Bcl6 clone ln22

Manufactured by Agilent Technologies

Bcl6 (clone LN22) is a lab equipment product offered by Agilent Technologies. It is a monoclonal antibody that recognizes the Bcl6 protein, which is a transcriptional repressor involved in the regulation of germinal center B-cell development.

Automatically generated - may contain errors

Lab products found in correlation

Myc clone y69, by Abcam (5 mentions) Mum1 clone mum1p, by Agilent Technologies (5 mentions) Cd10 clone 56c6, by Agilent Technologies (5 mentions) Bcl2 clone 124, by Agilent Technologies (4 mentions) Cd20 clone l26, by Abcam (3 mentions) Ki 67 clone mib 1, by Agilent Technologies (1 mentions)

5 protocols using bcl6 clone ln22

Immunohistochemistry Panel for Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was performed on 4-μm FFPE sections. Antibodies used in the study were CD20 (clone L26, Abcam, cutoff: 30%), CD10 (clone 56C6, Dako, cutoff: 30%), MUM1 (clone MUM1p, Dako), Bcl6 (clone LN22, Dako, cutoff: 30%), Myc (clone Y69; Abcam, cutoff: 40%) and Bcl2 (clone 124; Dako, cutoff: 50%). Cutoff scores for each antibody were described previously [2 (link), 19 (link)].

Wu S., Zhou Y., Hua H.Y., Zhang Y., Zhu W.Y., Wang Z.Q., Li J., Gao H.Q., Wu X.H., Lu T.X, & Hua D. (2018). Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma. BMC Cancer, 18, 997.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC (Figure 6) was performed on 4 μm sections with formalin-fixed paraffin-embedded (FFPE) specimens. Antibodies applied in the study including CD10 (clone 56C6; Dako, cut-off: 30%), MYC (clone Y69; Abcam, cut-off: 40%), BCL2 (clone 124; Dako, cut-off: 50%), BCL6 (clone LN22; Dako, cut-off: 30%), and MUM1 (clone MUM1p; Dako, cut-off: 30%). The COO was classified according to Hans algorithm [32 (link)].

Lu T.X., Fan L., Wang L., Wu J.Z., Miao K.R., Liang J.H., Gong Q.X., Wang Z., Young K.H., Xu W., Zhang Z.H, & Li J.Y. (2015). MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. Oncotarget, 6(21), 18374-18388.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Lymphoma Subtypes

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies applied in the study, according to the manufacturer’s instructions, included CD5 (clone EP2952, Abcam, cut-off: 30%), CD10 (clone 56C6, Dako, cut-off: 30%), CD30 (clone CON6D/B5, Abcam, cut-off: 30%), Ki-67 (clone Mib-1, Dako), Myc (clone Y69, Abcam, cut-off: 40%), Bcl2 (clone 124, Dako, cut-off: 50%), Bcl6 (clone LN22, Dako, cut-off: 30%), MUM1 (clone MUM1p, Dako, cut-off: 30%), FOXP1 (clone JC12, Abcam, cut-off: 60%), GCET1 (clone RAM341; Abcam, cut-off: 60%) and LMO2 (clone 1A9-1, Santa Cruz, cut-off: 30%). The cell of origin (COO) was classified according to Hans, Choi, Tally and Visco-Young algorithms. The specific cut-off of each antibody used in different algorithms was described previously21 (link)22 (link)23 (link)24 (link).

Lu T.X., Liang J.H., Miao Y., Fan L., Wang L., Qu X.Y., Cao L., Gong Q.X., Wang Z., Zhang Z.H., Xu W, & Li J.Y. (2015). Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Scientific Reports, 5, 12168.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC was performed on 4-μm FFPE sections. The antibodies used were CD10 (clone 56C6, Dako), CD20 (clone L26, Abcam), Bcl6 (clone LN22, Dako), and MUM1 (clone MUM1p, Dako), Myc (clone Y69; Abcam, cut-off: 40%) and Bcl2 (clone 124; Dako, cut-off: 50%) (Figure S1). The cut-off scores for each antibody were described previously9 (link)19 (link). Cases positive for both CD10 and MUM1were classified as DP group. Cases negative for CD10, Bcl6 and MUM1 were defined as TN group. Cases positive for both Myc and Bcl2 or Bcl6 were defined as double expression lymphoma (DEL)19 (link).

Lu T.X., Miao Y., Wu J.Z., Gong Q.X., Liang J.H., Wang Z., Wang L., Fan L., Hua D., Chen Y.Y., Xu W., Zhang Z.H, & Li J.Y. (2016). The distinct clinical features and prognosis of the CD10+MUM1+ and CD10−Bcl6−MUM1− diffuse large B-cell lymphoma. Scientific Reports, 6, 20465.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was performed on 4-μm formalin-fixed paraffin-embedded sections. The antibodies used in the study were for CD20 (clone L26, Abcam, cutoff: 30%), CD10 (clone 56C6, Dako, cutoff: 30%), Bcl6 (clone LN22, Dako, cutoff: 30%), MUM1 (clone MUM1p, Dako, cutoff: 30%), and Myc (clone Y69; Abcam, cutoff: 40%). The cutoff values for each antibody have been previously described [7 (link)].

Lu T.X., Wu S., Cai D.Y., Hong T.T., Zhang Y., Gao H.Q., Hua H.Y, & Wu X.H. (2019). Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma. BMC Cancer, 19, 553.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!